Physician profile

Evan D Frank

Interventional Pain Medicine · Wynnewood, PA

NPI 1356383368

$571.65

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$172.34

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Nevro Corp. $159.03 2019-2023 Senza
Spr Therapeutics, INC $116.16 2022
Vertos Medical, INC. $91.63 2023 Mild Device Kit
Grt US Holding, INC. $49.58 2022
Stryker Corporation $39.74 2024 Mild Device Kit
Assertio Therapeutics, INC. $36.43 2019
Abbott Laboratories $20.79 2023 Proclaim
Arbor Pharmaceuticals, INC. $17.45 2019
Lilly USA, LLC $15.14 2020
Boston Scientific Corporation $13.20 2019
Allergan, INC. $12.50 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Evan D Frank

$571.65

in general payments reported 2019-2025

Years
2019-2024
Top company
Nevro Corp.

https://glasscript.com/doctor/15671/evan-d-frank

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.